Detalimogene coraplasmid shows a promising CR rate for high-risk, BCG-unresponsive non-muscle invasive bladder cancer, with 63% achieving CR at any time. The treatment is well tolerated, with 42% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results